Pioneered byMichael Benatar, now the head of ALS at the University of Miami, these trials enroll and monitor carriers foryears, in hope of tracking precisely what changes, physiologic or molecular, arise right before the disease. In turn,researchers might look for those changes in both genetic carriers and the wider population and enroll all ALSpatients in clinical trials before the neuronal damage is irreparable.